AccuDial expands packaging portfolio with Stephen Key acquisition
PALM BEACH GARDENS, Fla. — AccuDial Pharmaceutical on Tuesday acquired Stephen Key Design in a move that will expand AccuDial’s patent portfolio to more than 50 patents for weight-based dosing and other extended content rotating labels, which add 75% more labeling space to a container.
“Stephen Key founded the company in 1998 and is a recognized leader in the $63 billion label industry," AccuDial chairman and CEO Bob Terwilliger said. "He will remain at the helm of Stephen Key Design and continue as a member of AccuDial’s board of directors."
“In the past 13 years, hundreds of millions of Spinformation labels have been used on a wide range of products,” Stephen Key said. “Spinformation labels have been used on Rexall Sundown Vitamins, Children’s AccuDial pediatric liquid medicines, and Kirkwood Brand products, to name just a few. Spinformation has partnerships with a number of packaging industry leaders.”
Stephen Key Design will focus with AccuDial on pharmaceutical applications for prescription, over-the-counter, nutritional supplements and injectable vials.
In addition to weight-based dosing, AccuDial’s ECRL can be used for product launches to notify consumers about a new or improved product; discount coupons on the inner label; quick reader codes can lead consumers to a company’s Twitter, Facebook, LinkedIn, YouTube, Flickr, Plaxo, Yelp, FourSquare, Digg, Delicious, StumbleUpon, Whrrl and MySpace profiles; multilanguage messaging on the inner label providing directions for multiple markets; illustrations, such as Barrier Grid animation, to illustrate such conditions as a throbbing pain in the shoulder or lower back; and daily dose and progress tracking for medicine taken multiple times per day.
Beginning Oct. 17, Children’s AccuDial acetaminophen for pain and fever with weight-based dosing will be available at Amazon.com, and a number of leading internet drug store sites. Children’s AccuDial acetaminophen for pain and fever will be available in five flavors: cherry, dye-free cherry, bubblegum, strawberry and grape for children between 12 and 95 lbs.
Ralph Neas delivers remarks at GPhA-FDA Fall Technical Conference
WASHINGTON — Though his term as Generic Pharmaceutical Association president and CEO began four weeks ago, Ralph Neas made his big debut Tuesday as he delivered his remarks at the GPhA-Food and Drug Administration Fall Technical Conference.
Neas — who most recently served as president and CEO of the National Coalition on Health Care and has long worked for various civil rights organizations — spoke of the growth of generic drugs over the years, noting that they account for 78% of all prescriptions dispensed in the United States despite consuming 25% of total drug spending. He also noted a recent analysis by IMS Health that showed the use of generic drugs saved consumers, patients and the U.S. healthcare system $931 billion over the past decade.
"These are incredible savings for the system and something each of us can share pride in helping to achieve," Neas said. "But we should not lose sight of what this means for individuals … to folks like you and me."
Click here to read the Neas’ full speech.
NCPA offers Senate tips for reducing Medicare Part D fraud, waste, abuse
ALEXANDRIA, Va. — The National Community Pharmacists Association is recommending several ways for reducing Medicare Part D fraud, waste and abuse to the Senate Homeland Security and Government Affairs subcommittee, the group said Tuesday.
"NCPA and its members remain committed to combating waste, fraud and abuse within federal health care programs, and stand at the ready to assist with these efforts," comments submitted by the group read. "It is important for Congress to also focus on the existing waste within and potential savings from how pharmacy benefit managers operate in the Medicare Part D program. In the end, NCPA seeks to partner with the federal government in the right way to generate healthcare savings, while providing high quality health care to our patients."
Recommendations included: ensuring that requirements to use National Provider Identifier numbers on Part D claims provide for an adequate transition to avoid inadvertently penalizing pharmacies acting in good faith to serve patients; ensuring the government receives billions of dollars in manufacturer rebate savings currently retained by PBMs; promoting the appropriate use of generic prescription drugs; and requiring Part D plans to implement consistent pharmacy audit practices to strengthen fraud protections and focus on true fraud.